Maja Lindstrom Joins Angelo Gordon as Managing Director as Firm Establishes Presence in the Nordics
Angelo, Gordon & Co., L.P. (“Angelo Gordon” or the “Firm”), a $73* billion alternative investment firm focused on credit and real estate investing, today announced that Maja Lindstrom, former Managing Director, EMEA Business Development at Barings, has joined the Firm as a Managing Director in its Client Partnership Group. A seasoned executive with more than 15 years of business development and investor relations experience, Ms. Lindstrom will spearhead the expansion of Angelo Gordon’s client base in Northern Europe and Israel. Based in Copenhagen, she reports to Alan Isenberg, Global Head of Angelo Gordon’s Client Partnership Group.
“We are thrilled to welcome Maja to Angelo Gordon as we seek to expand our boots-on-the-ground presence and institutional network in Europe,” said Mr. Isenberg. “We believe Maja’s significant experience and broad institutional relationships position us well to bring new opportunities to a highly sophisticated investor community.”
“Angelo Gordon is well-recognized by institutional investors globally, and I am pleased to join the Firm at this exciting time in its evolution. I look forward to helping grow and diversify our client base while also servicing existing longstanding Angelo Gordon partners,” Ms. Lindstrom added.
Prior to Barings, Ms. Lindstrom served as a Director, EMEA Business Development at Babson Capital Management. Earlier in her career, she held roles on the investor relations and sales teams at Armajaro Asset Management and Storm Capital Management. Ms. Lindstrom graduated with honors from Westminster University, with a Bachelor of Arts in Business and concentrations in finance and marketing.
ABOUT ANGELO, GORDON & CO., L.P.
Angelo, Gordon & Co., L.P. (“Angelo Gordon”) is a leading alternative investment firm founded in November 1988. The firm currently manages approximately $73 billion* with a primary focus on credit and real estate strategies. Angelo Gordon has over 650 employees, including more than 200 investment professionals, and is headquartered in New York, with associated offices elsewhere in the U.S., Europe, and Asia. For more information, visit www.angelogordon.com.
*Angelo Gordon’s (the "firm") currently stated AUM of approximately $73 billion as of December 31, 2022 reflects fund-level asset-related leverage. Prior to May 15, 2023, the firm calculated its AUM as net assets under management excluding leverage, which resulted in firm AUM of approximately $53 billion as of December 31, 2022. The difference reflects a change in the firm’s AUM calculation methodology and not any material change to the firm’s investment advisory business. For a description of the factors the firm considers when calculating AUM, please see the disclosure linked here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913598701/en/
Contact information
MEDIA
For Angelo Gordon:
Kaitlin Bilby / Stephanie Barry
(212) 692-8231 / (212) 692-8266
Media@angelogordon.com
Amanda Shpiner/Nathaniel Garnick
Gasthalter & Co.
(212) 257-4170
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Despite Continued Economic Volatility, Global Financial Inclusion Improved According to the Global Financial Inclusion Index from Principal ®3.10.2023 07:01:00 CEST | Press release
Singapore is the world’s most financially inclusive market across 42 analyzed, alongside Hong Kong, Switzerland, the United States, and Sweden, according to the second edition of the Global Financial Inclusion Index (the Index) from Principal Financial Group®. The research released today, conducted by the Centre for Economics and Business Research (Cebr) and Principal®, examines how well a market’s respective government, financial system, and employers provide relevant tools, services, and guidance to enable greater levels of financial inclusion. Now in its second year, the report provides a comprehensive and comparative evaluation of financial inclusion on a global scale – ranking 42 markets on a relative basis in addition to a new absolute score assigned at the global and regional levels. This enables the identification and analysis of regions making the most progress and those facing the greatest challenges. “Despite the uncertain economic conditions of the past year, it’s encouragi
ARMA Instruments Launch Zero Trust G1 Mark II Secure Messaging Communication Device3.10.2023 05:00:00 CEST | Press release
The Russian invasion of Ukraine has ignited an arms race in the theater of cyber warfare. Zero trust is the operative term for military, defense sectors, and governments across the globe. U.S. intelligence agencies and international partners recently published a report warning of the new Russian malware program Sandworm, likely targeting Ukrainian interests in its ongoing war, and U.S. defense agencies set a deadline of 2027 for implementation of zero trust cybersecurity environments [FedTech, August 2023]. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231002887540/en/ Switzerland-based ARMA Instruments AG announces the launch of their ARMA G1 Mark II Secure Messaging Device. Developed with zero trust principles, the device is a closed mobile system for person-to-person messaging at the highest security levels to counter advanced adversary attacks. The device will be beneficial for NGOs, defense agencies, cybersecurity oper
SLB Launches Carbon Storage Screening and Ranking Solution3.10.2023 04:00:00 CEST | Press release
SLB (NYSE: SLB) today launched its carbon storage screening and ranking solution that increases confidence in site selection decisions based on scientific analysis of the long-term integrity and economic potential of an asset. The solution helps customers avoid suboptimal storage sites with risk factors that can waste valuable time and resources as well as decrease the probability of a carbon capture, utilization and storage (CCUS) project reaching final investment decision (FID). “CCUS is one of the most immediate opportunities to reduce emissions, but it must scale up by 100–200 times in less than three decades to have the expected impact on global net zero ambitions,” said Frederik Majkut, senior vice president of Carbon Solutions for SLB’s New Energy business. “Ensuring that a storage site is both safer and economical is crucial for the speed, scale and investment needed to meaningfully drive CCUS growth for a low carbon energy ecosystem.” The screening and ranking solution uses bo
Takeda Provides Update on EXKIVITY ® (mobocertinib)2.10.2023 22:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY® (mobocertinib) in the U.S. for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-based chemotherapy. Takeda intends to similarly initiate voluntary withdrawal globally where EXKIVITY is approved and is working with regulators in other countries where it is currently available on next steps. This decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint and thus did not fulfill the confirmatory data requirements of the Accelerated Approval granted by the U.S. FDA nor the conditional marketing approvals granted in other countries. The EXCLAIM-2 trial was a Phase 3
Galderma announces progress with RelabotulinumtoxinA regulatory submissions2.10.2023 22:27:00 CEST | Press release
Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”). The FDA has issued a Complete Response Letter (“CRL”) to Galderma related to its BLA for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adult patients as well as moderate-to-severe lateral canthal lines (crow’s feet) associated with orbicularis oculi muscle activity in adult patients. The CRL points out certain deficiencies isolated to items related to Chemistry, Manufacturing, and Controls (“CMC”) processes. All other aspects of the BLA, including safety and efficacy related parts, did not solicit deficiencies to be addressed. Galderma has already identified changes to the manufacturing process to address feedback. It will also